<div id="readability-page-1"><p>Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on November 19th. The trade occurred in the Representative's &#34;150 MAIN STREET TRUST &gt; BANK OF AMERICA&#34; account.</p><ul><li>How Does D-Wave Stack Up Against Quantum Competitors?</li></ul><p>Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s): </p><ul><li>Sold $1,001 - $15,000 in shares of Spotify Technology <span>NYSE: SPOT<span></span></span> on 11/26/2025. </li><li>Sold $1,001 - $15,000 in shares of Alphabet <span>NASDAQ: GOOGL<span></span></span> on 11/26/2025. </li><li>Purchased $1,001 - $15,000 in shares of First Watch Restaurant Group <span>NASDAQ: FWRG<span></span></span> on 11/26/2025. </li><li>Purchased $1,001 - $15,000 in shares of TKO Group <span>NYSE: TKO<span></span></span> on 11/26/2025. </li><li>Sold $1,001 - $15,000 in shares of RBC Bearings <span>NYSE: RBC<span></span></span> on 11/24/2025. </li><li>Sold $1,001 - $15,000 in shares of Stifel Financial <span>NYSE: SF<span></span></span> on 11/24/2025. </li><li>Purchased $1,001 - $15,000 in shares of Logan Energy <span>CVE: LGN<span></span></span> on 11/24/2025. </li><li>Sold $1,001 - $15,000 in shares of Primoris Services <span>NASDAQ: PRIM<span></span></span> on 11/24/2025. </li><li>Purchased $15,001 - $50,000 in shares of LandBridge <span>NYSE: LB<span></span></span> on 11/21/2025. </li><li>Purchased $50,001 - $100,000 in shares of LandBridge <span>NYSE: LB<span></span></span> on 11/20/2025. </li></ul><h2>AstraZeneca Stock Performance</h2><p>Shares of NASDAQ:AZN traded down $1.49 during midday trading on Wednesday, reaching $89.86. The company's stock had a trading volume of 5,973,979 shares, compared to its average volume of 5,193,033. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. The stock has a fifty day moving average of $87.26 and a 200 day moving average of $79.50. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $94.01. The firm has a market capitalization of $278.69 billion, a PE ratio of 29.85, a P/E/G ratio of 1.70 and a beta of 0.32. </p><ul><li>Tempus AI Stock: Time to Double Down or Cut and Run?</li></ul><p>AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.14 by $0.05. The company had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The firm's quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.08 earnings per share.  On average, equities analysts expect that  AstraZeneca PLC will post 4.51 EPS for the current fiscal year. </p><h2>Analyst Ratings Changes</h2><p>Several brokerages have recently weighed in on AZN. HSBC  reaffirmed a &#34;buy&#34; rating and set a $108.00 target price on shares of AstraZeneca in a research note on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Thursday, October 16th. Cowen  restated a &#34;buy&#34; rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Guggenheim  reiterated a &#34;buy&#34; rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Finally, Weiss Ratings  reiterated a &#34;buy (b)&#34; rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating and one  has issued  a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $95.75.</p><ul><li>Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal</li></ul><p><b>Check Out Our Latest Report on AstraZeneca</b></p><h2>Institutional Trading of AstraZeneca</h2><p>Hedge funds have recently bought and sold shares of the business. NewSquare Capital LLC grew its position in shares of  AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company's stock valued at $25,000 after purchasing an additional 218 shares in the last quarter.  Triumph Capital Management acquired a new position in  AstraZeneca during the third quarter worth $25,000.  Richardson Financial Services Inc. boosted its stake in  AstraZeneca by 59.8% during the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company's stock worth $28,000 after buying an additional 149 shares during the last quarter.  Rakuten Investment Management Inc. purchased a new stake in  AstraZeneca in the 3rd quarter valued at $31,000.  Finally, FSA Wealth Management LLC increased its stake in shares of  AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company's stock worth $33,000 after acquiring an additional 376 shares during the last quarter. Institutional investors and hedge funds own  20.35% of the company's stock. </p><h2>About Representative Cisneros</h2><p>Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.  Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election.  Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.</p><h2>AstraZeneca Company Profile</h2> (Get Free Report)<p>AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.</p><h2>Read More</h2><ul><li>Five stocks we like better than AstraZeneca</li><li>What does consumer price index measure? </li><li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li><li>Quiet Period Expirations Explained</li><li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li><li>How to Invest in Small Cap Stocks </li><li>Is Tesla Overvalued? 2 Reasons It Might Be a Bargain</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AstraZeneca Right Now?</h2><p>Before you consider AstraZeneca, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.</p><p>While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Rep. Gilbert Ray Cisneros, Jr. (D-California) purchased AstraZeneca PLC shares worth $1,001-$15,000. AstraZeneca's stock traded at $89.86, with a market cap of $278.69 billion. Analysts have mixed ratings, with a consensus price target of $95.75. Recent earnings beat estimates, with $1.19 EPS and $15.19 billion revenue. Institutional investors are actively trading AstraZeneca shares.</p>

Rep. Gilbert Ray Cisneros, Jr. Buys AstraZeneca PLC (NASDAQ:AZN) Stock